Mary Tipton, MD
Pediatrics · West Jordan, UTNPI 1922065598
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. GSK accounts for 74.8% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $8,127 and has fallen 99.8% since, to $15 in 2025. Among pediatrics clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $72.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$12K
- AstraZeneca$1K
- AbbVie$471
- Lilly USA, LLC$364
- Abbott$259
- Novo Nordisk$245
- plus $1K from 30 others
Across 483 payments — averaging $5872.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1.1M
- Merck$832K
- Pfizer$464K
- Sanofi Pasteur Inc.$313K
- AstraZeneca$102K
- Astrazeneca UK Limited$29K
What the payments were for
- Consulting fees$7,20545%
- Travel & lodging$4,95031%
- Food & beverage$3,98925%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 31 | $12,079 |
| AstraZeneca | 21 | $1,400 |
| AbbVie(2 entities) | 22 | $471 |
| Lilly USA, LLC | 23 | $364 |
| Abbott | 10 | $259 |
| Novo Nordisk | 23 | $245 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $122 |
| Boehringer Ingelheim | 7 | $116 |
| Merck | 12 | $111 |
| Sunovion Pharmaceuticals Inc. | 6 | $87 |
| Biohaven Pharmaceuticals, Inc. | 4 | $83 |
| Pfizer | 12 | $77 |
| Vistapharm, Inc. | 4 | $76 |
| Boston Scientific | 3 | $67 |
| Sobi, Inc | 2 | $63 |
| Sanofi-aventis U.S. LLC | 4 | $55 |
| Johnson & Johnson | 3 | $52 |
| Cranial Technologies, Inc | 3 | $45 |
| Supernus Pharmaceuticals, Inc. | 3 | $44 |
| Ironshore Pharmaceuticals Inc. | 3 | $38 |
| Mannkind Corporation | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Eisai Inc. | 1 | $23 |
| Therapeuticsmd, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Corium, LLC | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Alkermes, Inc. | 1 | $17 |
| Amgen | 1 | $15 |
| Apria Healthcare LLC | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Dexcom, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEXSERO$6,000
- MENVEO$3,695
- FreeStyle Libre Pro$135
How this compares
$16,145 in reported general payments places this provider in the 95th percentile of 439 pediatrics providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $37,588 |
| MounjaroTirzepatide | 18 | $26,004 |
| JardianceEmpagliflozin | 14 | $17,214 |
| EliquisApixaban | 14 | $15,836 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $6,510 |
| Gabapentin | 32 | $1,544 |
| Omeprazole | 58 | $1,386 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 17 | $1,284 |
| Levothyroxine Sodium | 84 | $1,182 |
| Atorvastatin Calcium | 117 | $1,118 |
| Estradiol | 22 | $1,081 |
| Duloxetine Hcl | 27 | $1,075 |
| SynthroidLevothyroxine Sodium | 16 | $1,013 |
| Olmesartan Medoxomil | 31 | $906 |
| Bupropion XlBupropion Hcl | 30 | $757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $245 | $37,58829 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $364 | $26,45632 claims |
| Boehringer IngelheimJardiance | $116 | $17,21414 claims |
| PfizerEliquis | $77 | $15,83614 claims |
| AbbVieSynthroid | $471 | $1,01316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 439 pediatrics providers in Utah.
Other pediatrics in West Jordan
- Valerie RahaniotisWest Jordan$2K
- Christopher CookWest Jordan$2K
- Helen AokiWest Jordan$1K
- Joshua MaxwellWest Jordan$1K
- David NuttallAmerican Fork$307K
- Mari LuceLayton$289K
- Brian ShayotaSalt Lake City$93K
- Rodney PollaryLehi$56K
- Laura SavageProvo$49K
- Ashley AndrewsSalt Lake City$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.